This public meeting will be to obtain comments regarding behind-the-counter availability of drugs. Currently, drugs are available as prescription and non-prescription. Generally, non-prescription products are available in an "over-the-counter" manner. The FDA is interested in obtaining public comment as it explores the public health benefit of certain drugs being available without a prescription but only after intervention by a pharmacist. The purpose of the meeting is to solicit information and views from interested persons on specific issues associated with BTC availability, including the impact on patient access to safe and effective drug products.
When:
Nov. 14, 2007, 8 a.m.-5 p.m.
Where:
National Transportation Safety Board Conference Center
429 L'Enfant Plaza SW.,
Washington, DC 20594.
Registration:
Seating at the meeting is limited. People interested in attending should submit written or electronic registration to the Division of Docket Management by close of business on Nov. 5, 2007. Registration is free and will be on a first-come, first-serve basis.
Submit registration to:
Division of Dockets Management (HFA-305)
Food and Drug Administration,
5630 Fishers Lane, rm. 1061
Rockville, MD 20852.
Submit electronic registration.
Transcripts of the meeting will be available for review at the Division of Dockets Management and online approximately 30 days after the meeting.
Meeting contact:
Erik Mettler
Office of Policy (HF-11)
Food and Drug Administration
5600 Fishers Lane, rm. 14-101
Rockville, MD 20857
301-827-3360
Fax: 301-594-6777
e-mail: Erik.Mettler@fda.hhs.gov.
For more background, visit the meeting notice.